IP Library › Granted Patent US 12,544,351
Granted Patent B2
US 12,544,351 · App. 17/440,246 · Granted Feb 10, 2026

Methods using medium chain triglycerides administered prior to a meal to decrease postprandial glucose from the meal

Inventor: Bernard Cuenoud (Cully, CH)
Assignee: Societe des Produits Nestle S.A.
A61K31/23A61K9/0053A61P3/10
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,544,351
App. No.
17/440,246
Granted
Feb 10, 2026
Kind
B2
Abstract

A method reduces postprandial glucose from a meal. The method includes orally administering to an individual a composition containing medium chain triglycerides (MCT) and then subsequently orally administering the meal to the individual after the oral administration of the composition containing the MCTs and within about one hour of the oral administration of the composition containing the MCTs. For example, the meal can be administered about thirty minutes after the administration of the composition containing the MCTs. The postprandial glucose is reduced relative to postprandial glucose from (i) postprandial glucose from administration of an identically formulated composition containing MCTs at approximately the same time as the administration of the meal and (ii) postprandial glucose from administration of the meal without any MCTs within about one hour before or within about one hour afterward. The composition containing the MCTs can be a liquid oral nutritional supplement (ONS) providing incomplete nutrition.

Claims (20)

1 . A method of reducing postprandial glucose in an individual from a meal, the individual having at least one condition selected from the group consisting of diabetes and pre-diabetes, the method comprising:

orally administering to the individual a composition comprising medium chain triglycerides (MCTs), wherein the composition is administered to the individual in a serving comprising at least about 15.0 g of the MCTs up to about 30.0 g of the MCTs; and

subsequently orally administering the meal to the individual after the orally administering the composition comprising the MCTs and within about one hour of the orally administering the composition comprising the MCTs.

2 . The method of claim 1 , wherein the individual is an aging subject.

3 . The method of claim 2 , wherein the individual is elderly.

4 . The method of claim 1 , wherein the composition comprises the MCTs emulsified in at least one additional component selected from the group consisting of a protein, a lipid, a carbohydrate, and an emulsifier.

5 . The method of claim 1 , wherein the meal is administered between about ten minutes after the orally administering the composition comprising the MCTs and about one hour after the orally administering the composition comprising the MCTs.

6 . The method of claim 1 , wherein the meal is breakfast.

7 . The method of claim 1 , wherein at least a portion of the MCTs comprises at least one of octanoic acid or decanoic acid.

8 . The method of claim 1 , wherein the postprandial glucose in the individual is reduced relative to postprandial glucose from at least one comparative situation selected from the group consisting of (i) orally administering the meal and the composition comprising the MCTs to the individual at approximately the same time and (ii) orally administering the meal without any MCTs within about one hour before or within about one hour afterward.

9 . The method of claim 1 , wherein the composition is a liquid incomplete nutrition oral nutritional supplement (ONS).

10 . The method of claim 1 , wherein the individual does not consume any food products other than optional water during a time period from the orally administering the composition comprising the MCTs to the individual to the orally administering the meal to the individual.

11 . A method of reducing or improving at least one symptom of at least one condition in an individual in need thereof or at risk thereof for which reduced postprandial glucose from a meal is beneficial, wherein the at least one condition is selected from the group consisting of pre-diabetes and diabetes, the method comprising:

orally administering to the individual a composition comprising medium chain triglycerides (MCTs), wherein the composition is administered to the individual in a serving comprising at least about 15.0 g of the MCTs up to about 30.0 g of the MCTs; and

subsequently orally administering the meal to the individual after the orally administering the composition comprising the MCTs and within about one hour of the orally administering the composition comprising the MCTs,

wherein the meal comprises at least one of a fat or a protein, and

the orally administering of the composition and the subsequent orally administering of the meal reduces the postprandial glucose in the individual from the meal.

12 . The method of claim 11 , wherein the meal is administered between about ten minutes after the orally administering the composition comprising the MCTs and about one hour after orally administering the composition comprising the MCTs.

13 . The method of claim 11 , wherein the meal is administered between about fifteen minutes after the orally administering the composition comprising the MCTs and about forty minutes after the orally administering the composition comprising the MCTs.

14 . The method of claim 11 , wherein the meal is administered about thirty minutes after the orally administering the composition comprising the MCTs.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 1, 2022
From: CUENOUD, BERNARD
To: NESTEC S.A.
Reel/Frame 059476/0848 →
MERGER Recorded Apr 1, 2022
From: NESTEC S.A.
To: SOCIETE DES PRODUITS NESTLE S.A.
Reel/Frame 059477/0093 →
Continuity (2)
Provisional Application 62822271 · Mar 22, 2019
Related Publication 20220168257A1 · Jun 2, 2022
References Cited (29)
US 20040076719A1 · Pimentel · 2004 [cited by applicant]
EP 0691079A2 · 1996 [cited by applicant]
EP 1269859A2 · 2003 [cited by applicant]
EP 1421858A1 · 2004 [cited by applicant]
JP 2016514725A · 2016 [cited by applicant]
WO 2009118968 · 2009 [cited by applicant]
WO 2011118810A1 · 2011 [cited by applicant]
Nathan, David M., “Diabetes: Advances in Diagnosis and Treatment”, 2015, JAMA, 314, pp. 1052-1062 (Year: 2015). [cited by examiner]
Buse et al., “How do we define cure of diabetes?”, 2009, Diabetes Care, 32, pp. 2133-2135 (Year: 2009). [cited by examiner]
St-Onge et al., “Impact of medium and long chain triglycerides consumption on appetite and food intake in overweight men” European Journal of Clinical Nutrition, 2014, vol. 68, pp. 1134-1140 (Year: 2014). [cited by examiner]
“NEOBEE(R) 1053”, 2024, Stepan Company, 2 pgs. (Year: 2024). [cited by examiner]
Tricò et al., “Sustained effects of a protein and lipid preload on glucose tolerance in type 2 diabetes patients”, 2016, Diabetes & Metabolism, 42, pp. 242-248 (Year: 2016). [cited by examiner]
Hunter et al., “Parmesan Cheese Nutrients”, 2024, Nutrivore, 17 pgs. (Year: 2024). [cited by examiner]
“Bulletproof(R) Coffee Making Kit”, 2013, OptimOZ, 4 pgs. (Year: 2013). [cited by examiner]
Kruk et al., “Water mobility in cheese by means of Nuclear Magnetic Resonance relaxometry”, 2021, Journal of Food Engineering, 298, pp. 1-7 (Year: 2021). [cited by examiner]
Nutritionix, “Butter, salted—1 stick”, 2016, Syndigo, 3 pgs. (Year: 2016). [cited by examiner]
Bell, “Importance of Postprandial Glucose Control”, 2001, Southern Medical Association, 94, Abstract only (Year: 2001). [cited by examiner]
Abdullah et al., “The magnitude of association between overweight and obesity and the risk of diabetes: A meta-analysis of prospective cohort studies”, 2010, Diabetes Research and Clinical Practice, 89, pp. 309-319 (Yea… [cited by examiner]
Nagaoka, “Yogurt Production”, Lactic Acid Bacteria: Methods and Protocols, available online 2018, Springer Nature, 1887, pp. 45-54 (Year: 2018). [cited by examiner]
Courchesne-Loyer et al. “Emulsification increases the acute ketogenic effect and bioavailability of medium- chain triglycerides in humans”, Current Developments in Nutrition, Jul. 1, 2017, vol. 1, No. 7, 32 pages, XP556… [cited by examiner]
Xin et al., “Nutritional Ketosis Increases NAD+/NADH Ratio in Healthy Human Brain: An in Vivo Study by 31P-MRS”, Frontiers in Nutrition, vol. 5, Jul. 12, 2018, pp. 1-8. [cited by applicant]
Myette-Cote et al., “Prior Ingestion of Exogenous Ketone Monoester Attenuates the Glycaemic Response to an Oral Glucose Tolerance Test in Healthy Young Individuals”, The Journal of Physiology, vol. 596, Issue No. 8, 201… [cited by applicant]
Japanese Office Action for Appl No. 2021-551585 dated Feb. 13, 2024. [cited by applicant]
European Office Action for Appl No. 20 713 864.5-1112 dated Jan. 3, 2024. [cited by applicant]
St-Onge et al. “Impact of medium and long chain triglycerides consumption on appetite and food intake in overweight men” European Journal of Clinical Nutrition, 2014, vol. 68, pp. 1134-1140. [cited by applicant]
Yost et al. “Dietary Substitution of Medium Chain Triglycerides in Subjects with Non-Insulin-Dependent Diabetes Mellitus in an Ambulatory Setting: Impact on Glycemic Control and Insulin-Mediated Glucose Metabolism” Jour… [cited by applicant]
Flatt et al. “Effects of dietary fat on postprandial substrate oxidation and on carbohydrate and fat balances” The Journal of Clinical Investigation, 1985, vol. 76, No. 3, pp. 1019-1024. [cited by applicant]
Gee et al., “Efficacy of Low Residue Enteral Formula Versus Clear Liquid Diet during Bowel Preparation for Colonoscopy: A Randomised Controlled Pilot Trial”, Journal of Coloprotology, vol. 39, Issue No. 1, 2019, pp. 62-… [cited by applicant]
Japanese Office Action for Appl No. 2021-551585 dated May 14, 2024, 4 pages. [cited by applicant]